Is dyspareunia more common after menopause?

Yes. Declining estrogen at menopause causes vaginal atrophy, reduced lubrication, and loss of tissue elasticity — changes grouped under genitourinary syndrome of menopause (GSM). Estimates suggest 17–45% of postmenopausal women experience painful intercourse. Unlike hot flashes, which often ease over time, vaginal and sexual symptoms from GSM tend to worsen progressively unless treated.

Can vaginal estrogen cause cancer?

Local vaginal estrogen has a well-established safety profile. Because it acts directly on vaginal tissue with minimal systemic absorption, it is generally considered safe for most women — including many with a history of hormone-sensitive cancers — though this should always be discussed with a specialist familiar with your cancer history. The Menopause Society and SOGC both note that the benefits of treating GSM symptoms with local estrogen typically outweigh the very low systemic exposure involved.

Can dyspareunia be psychological?

Psychological factors — including anxiety, fear of pain, trauma history, and relationship difficulties — can contribute to or worsen dyspareunia, but this does not mean the pain is not real or not physical. In many cases, physical and psychological contributors coexist and reinforce each other. The most effective treatment usually addresses both dimensions; psychosexual therapy and pelvic floor physiotherapy are often recommended alongside any medical treatment.

Do lubricants fix dyspareunia?

Lubricants reduce friction and provide symptomatic relief during intercourse but do not treat the underlying cause. For dyspareunia driven by estrogen deficiency, lubricants ease discomfort but will not reverse vaginal tissue changes. Regular use of vaginal moisturizers (used daily, not only during sex) provides more sustained comfort. For lasting improvement in tissue health, treating the underlying hormonal deficit — with vaginal estrogen, prasterone, or systemic HRT — is more effective than lubricants alone.

How is dyspareunia different from vaginismus?

Dyspareunia is a broad symptom — persistent genital pain during or after sex — that can have many causes, including hormonal, structural, infectious, and psychological ones. Vaginismus is one specific cause of dyspareunia: involuntary contractions of the pelvic floor muscles at the vaginal opening that make penetration painful or impossible. The two conditions can coexist, and vaginismus can develop secondarily in people who have experienced painful intercourse from other causes. Pelvic floor physiotherapy is the primary treatment for vaginismus.

Dyspareunia — Glossary | Hormone Journal

What it is

Dyspareunia is persistent or recurrent genital pain occurring just before, during, or after sexual intercourse, affecting an estimated 10–20% of women at some point in their lives. Also called painful intercourse or painful sex, dyspareunia is not a diagnosis in itself but a symptom with many identifiable underlying causes, a significant proportion of which are hormonal. Surveys of postmenopausal Canadian women not using hormone therapy report dyspareunia in 20–45% of respondents — making it one of the most common and undertreated concerns in menopause care. Despite its impact on intimacy, relationships, and quality of life, many people never raise it with a clinician. It is both a medical symptom and a treatable one, and the underlying cause should always be investigated.

Pain may be felt at the vaginal entrance (superficial dyspareunia), deep within the pelvis during thrusting (deep dyspareunia), or both. It can present as sharp, burning, stinging, or a dull ache that lingers for hours after sex.

Causes and mechanism

Hormonal causes are the most common driver in women, particularly around menopause, postpartum, and during breastfeeding.

Hormonal causes

Estrogen deficiency — the leading cause in postmenopausal and breastfeeding women. Low estrogen thins vaginal tissue, reduces natural lubrication, and diminishes tissue elasticity, making penetration painful or impossible.
Genitourinary syndrome of menopause (GSM) — the umbrella term for the cluster of genital, urinary, and sexual symptoms that arise from declining estrogen. GSM is progressive: unlike hot flashes, vaginal and sexual symptoms worsen over time without treatment.
Hormonal contraceptives — some combined oral contraceptives suppress testosterone and reduce vulvar sensitivity and natural lubrication, contributing to entry pain.

Non-hormonal causes

Endometriosis — pelvic adhesions and inflammation cause deep dyspareunia, often position-dependent.
Vaginismus — involuntary pelvic floor muscle contractions at the vaginal opening that make penetration painful or impossible.
Vulvodynia — chronic vulvar pain without an identifiable structural cause.
Pelvic inflammatory disease (PID) — ascending infection causing pelvic tenderness and deep pain.
Skin conditions — lichen sclerosus or lichen planus affecting vulvar tissue.
Psychological factors — anxiety, trauma history, fear of pain, and relationship difficulties can initiate or perpetuate dyspareunia, and often coexist with physical causes.

Pain type	Common causes	Typical character
Superficial (entry)	Estrogen deficiency, GSM, vaginismus, vulvodynia, skin conditions	Burning, stinging, tearing at penetration
Deep (thrusting)	Endometriosis, PID, pelvic floor dysfunction, fibroids	Aching, pressure, cramping during or after sex
Mixed	Combination of above	Variable; may shift with position or cycle phase

Symptoms and diagnosis

Common presentations include pain at initial penetration, deep pelvic pain with thrusting, vaginal dryness or tightness, postcoital burning, and — in some cases — light bleeding after sex.

Diagnosis typically involves:

Detailed history — pain location, timing, triggers, and duration; reproductive and contraceptive history; menopausal or postpartum status; any history of pelvic surgery or trauma.
Pelvic examination — assessing vaginal tissue health, pelvic floor muscle tone, skin changes, and localizing tenderness.
Hormone panel — estradiol, FSH, LH, and testosterone to identify deficiency states. In Canada, these panels are available through LifeLabs and Dynacare with a physician or nurse practitioner requisition.
Infection screening — swabs to rule out STIs, bacterial vaginosis, and candidiasis.
Pelvic ultrasound or laparoscopy — when endometriosis or structural pathology is suspected.

Treatment options

Treatment targets the underlying cause. No single approach works for all presentations.

For hormonal causes (estrogen deficiency / GSM)

Vaginal estrogen (cream, ring, or pessary) — restores vaginal tissue health and lubrication with minimal systemic absorption. Considered safe for most women, including many who cannot use systemic hormone therapy. Available by prescription in Canada.
Systemic hormone therapy (HRT) — addresses both vaginal symptoms and broader menopausal symptoms where indicated.
Vaginal DHEA (prasterone / Intrarosa) — a daily vaginal insert converted locally to both estrogen and testosterone in vaginal tissue; approved in Canada.
Ospemifene (Osphena) — an oral selective estrogen receptor modulator (SERM) approved for moderate-to-severe dyspareunia from GSM. Note: carries a small risk of hot flashes, blood clots, and endometrial changes; discuss risks with your prescriber.

For endometriosis-related dyspareunia

Hormonal suppression (progestins, GnRH analogues, combined oral contraceptives) and, where appropriate, surgical removal of lesions.

For pelvic floor and muscle-related causes

Pelvic floor physiotherapy — highly effective for vaginismus and muscle-related dyspareunia; referral is available through most Canadian family physicians and gynecologists.
Graduated vaginal dilator therapy — used alongside physiotherapy.
Psychosexual or cognitive behavioural therapy — addresses anxiety, trauma, and conditioned pain responses that perpetuate dyspareunia even after physical causes are treated.

Symptomatic relief for all causes

Water-based or silicone-based lubricants reduce friction during intercourse. Regular use of vaginal moisturizers (not only during sex) provides more sustained comfort. These measures help but do not reverse underlying tissue changes.

Canadian patients can access prescription options through in-person gynecology or family medicine, or through virtual care platforms such as Felix, Maple, Cleo, or Phoenix — though a pelvic examination remains important for a complete assessment.

When to see a clinician in Canada

See a clinician if you experience pain during or after sex on more than one occasion. Dyspareunia is a medical symptom with identifiable causes — not something to endure or attribute solely to aging.

Seek prompt evaluation if:

Pain is sudden, severe, or accompanied by bleeding
Pain occurs outside of intercourse as well (at rest, during urination, or with tampon use)
You are going through a hormonal transition — menopause, postpartum, breastfeeding, or a recent change in hormonal contraception
Pain is affecting your relationship, mental health, or quality of life

The SOGC (Society of Obstetricians and Gynaecologists of Canada) recommends that all women experiencing GSM symptoms, including dyspareunia, be offered treatment rather than advised to simply manage with lubricants alone.

Limitations and open questions

Research is still emerging on the long-term outcomes of vaginal DHEA and ospemifene in women with hormone-sensitive cancer histories; current evidence is reassuring but guidelines vary by cancer type and treating oncologist. The optimal duration of vaginal estrogen therapy has not been firmly established — most guidelines support indefinite use where symptoms persist, but long-term safety data beyond 5 years remain limited. Health Canada has not yet issued specific guidance on the use of compounded vaginal hormones, and quality and dosing consistency across compounding pharmacies varies. The relationship between hormonal contraceptives and dyspareunia is real but incompletely characterized — not all formulations carry equal risk, and individual response varies considerably. Psychological and physical contributors to dyspareunia frequently coexist, but integrated care models combining physiotherapy, psychosexual therapy, and medical treatment remain underutilized and unevenly available across Canadian provinces.

Dyspareunia